Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?

Pharmacological Research

Volumn 62, Issue 5, 2010, Pages 439-443

  Gassani, Beatriz Carvalho Andraus ^a   Rezende, Rafael Machado ^a   Paiva Lima, Patrícia ^a   Ferreira Alves, Dalton L ^a   dos Reis, Webster Glayser Pimenta ^a   Bakhle, Y S ^b   de Francischi, Janetti Nogueira ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Analgesic activity; Celecoxib; Hyperalgesia; Lumiracoxib; Sulphonamide radical

Indexed keywords

ACETAZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FUROSEMIDE; LOOP DIURETIC AGENT; LUMIRACOXIB; NALTREXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; RADICAL; SULFONAMIDE; SULPHONAMIDE RADICAL; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; ENZYME INHIBITION; HYPOALGESIA; INFLAMMATION; MALE; MECHANICAL STIMULATION; NONHUMAN; PAIN; PAW EDEMA; PRIORITY JOURNAL; RAT;

ACETAZOLAMIDE; ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERALGESIA; INFLAMMATION; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 77956894498     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.06.007     Document Type: Article

References (21)

1. Francischi J.N., Chaves C.T., Moura A.C.L., Lima A.S., Rocha O.A., Ferreira-Alves D.L., et al. Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 2002, 137:837-844.
2. França D.S., Ferreira-Alves D.L., Duarte I.D., Ribeiro M.C., Rezende R.M., Bakhle Y.S., et al. Endogenous opioids mediate the hypoalgesia induced by inhibitors of cyclooxygenase-2 in rat paws treated with carrageenan. Neuropharmacology 2006, 51:37-43.
3. Correa J.D., Paiva-Lima P., Rezende R.M., Dos Reis W.G.P., Ferreira-Alves D.L., Bakhle Y.S., et al. Peripheral μ-, κ- and δ-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. Life Sci 2010, 86:951-956.
4. Penning T.B., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y1] benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 1997, 40:1347-1365.
5. Esser R., Berry C., Du Z., Dawson J., Fox A., Fujimoto R.A., et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005, 144:538-550.
6. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 6:109-110.
7. Pereira L.S., Ferreira-Alves D.L., Resende M.A., Romualdo M.A., Dos Reis W.G.P., Lopes M.T., et al. Reduced production of hyperalgesic substances by mononuclear cells from aged rats incubated with carrageenan: role of interleukin-2 and prostaglandins. Inflamm Res 2003, 52:119-125.
8. Rezende R.M., França D.S., Menezes G.B., dos Reis W.G., Bakhle Y.S., Francischi J.N. Different mechanisms underlie the analgesic actions of paracetamol and dipyrone in a rat model of inflammatory pain. Br J Pharmacol 2008, 153:760-768.
9. Rezende R.M., Dos Reis W.G., Duarte I.D., Lima P.P., Bakhle Y.S., de Francischi J.N. The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. Pain 2009, 142:94-100.
10. Randall L.O., Selitto J.J. A method for measurement of analgesic activity on inflamed tissues. Arch Int Pharmacodyn Ther 1957, 111:409-419.
11. Veeraveedu P.T., Watanabe K., Ma M., Thandavarayan R.A., Palaniyandi S.S., Yamaguchi K., et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol 2008, 75:649-659.
12. Radhakrishnan R., Sluka K.A. Acetazolamide, a carbonic anhydrase inhibitor, reverses inflammation-induced thermal hyperalgesia in rats. J Pharmacol Exp Ther 2005, 313:921-927.
13. Capuano A., De Corato A., Treglia M., Tringali G., Dello Russo C., Navarra P. Anti-nociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: a combination analysis study. Eur J Pharmacol 2009, 605:57-62.
14. Chichorro J.G., Lorenzetti B.B., Zampronio A.R. Involvement of bradykinin, cytokines, sympathetic amines and prostaglandins in formalin-induced orofacial nociception in rats. Br J Pharmacol 2004, 141:1175-1184.
15. Lizarraga I., Chambers J.P. Involvement of opioidergic and alpha2-adrenergic mechanisms in the central analgesic effects of non-steroidal anti-inflammatory drugs in sheep. Res Vet Sci 2006, 80:194-200.
16. Pernia-Andrade A.J., Tortorici V., Vanegas H. Induction of opioid tolerance by lysine-acetylsalicylate in rats. Pain 2004, 111:191-200.
17. - cotransporter blockers on formalin-induced nociception in rats. Pain 2005, 114:231-238.
18. Sung K.W., Kirby M., McDonald M.P., Lovinger D.M., Delpire E. Abnormal GABAA receptor-mediated currents in dorsal root ganglion neurons isolated from Na-K-2Cl cotransporter null mice. J Neurosci 2000, 20:7531-7538.
19. Laird J.M., García-Nicas E., Delpire E.J., Cervero F. Presynaptic inhibition and spinal pain processing in mice: a possible role of the NKCC1 cation-chloride co-transporter in hyperalgesia. Neurosci Lett 2004, 361:200-203.
20. Supuran C.T., Casini A., Scozzafava A. Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med Res Rev 2003, 23:535-558.
21. Smith D.A., Jones R.M. The sulfonamide group as a structural alert: a distorted story?. Curr Opin Drug Discov Dev 2008, 11:72-79.